Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Xu Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3768-777X; OpenAlex author ID A5017396752. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 8

  1. Neutrophils as promising therapeutic targets in pancreatic cancer liver metastasis. Last author DOI 10.1016/j.intimp.2024.112888↗
  2. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  3. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  4. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  5. Reciprocal regulation of LOXL2 and HIF1α drives the Warburg effect to support pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41419-021-04391-3↗
  6. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  7. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  8. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.21037/cco.2019.03.02↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhigang Zhang · 7 shared papers, 2019–2023 · strength 0.83
  2. Shu‐Heng Jiang · 7 shared papers, 2019–2023 · strength 0.83
  3. Li-Peng Hu · 6 shared papers, 2019–2023 · strength 0.67
  4. Qin Yang · 5 shared papers, 2021–2023 · strength 0.62
  5. Yongwei Sun · 4 shared papers, 2021–2023 · strength 0.52
  6. Qing Li · 4 shared papers, 2021–2023 · strength 0.46
  7. Rongkun Li · 3 shared papers, 2021–2023 · strength 0.39
  8. Dejun Liu · 3 shared papers, 2021–2023 · strength 0.36
  9. Minwei Yang · 3 shared papers, 2021–2023 · strength 0.34
  10. Minjie Guo · 1 shared paper, 2024 · strength 0.31
  11. Xueli Zhang · 3 shared papers, 2019–2021 · strength 0.30
  12. Lili Zhu · 2 shared papers, 2021 · strength 0.23
  13. Xin Xing · 2 shared papers, 2021 · strength 0.22
  14. Kaixia Zhou · 2 shared papers, 2021 · strength 0.20
  15. Linli Yao · 2 shared papers, 2021 · strength 0.20
  16. Shan Zhang · 1 shared paper, 2023 · strength 0.16
  17. Junfeng Zhang · 1 shared paper, 2023 · strength 0.16
  18. Rong Hua · 1 shared paper, 2023 · strength 0.16
  19. Dongxue Li · 1 shared paper, 2023 · strength 0.14
  20. Gary Guishan Xiao · 1 shared paper, 2023 · strength 0.14
  21. Hengchao Li · 1 shared paper, 2021 · strength 0.12
  22. Yongsheng Jiang · 1 shared paper, 2021 · strength 0.11
  23. Yan‐Miao Huo · 1 shared paper, 2021 · strength 0.10
  24. Jian‐Yu Yang · 1 shared paper, 2021 · strength 0.10
  25. Yifan Zhang · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.